This insider cluster is too small to warrant a trading signal. Monitor for any larger, unplanned open-market sales from C-suite executives, which would be more informative. The company's next pipeline catalyst (likely VAX-24 Phase 3 data) remains the primary driver for the stock.
PCVX drugs
PCVX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $58.89entry
- T+1 · 3mo ago −1.39%α −2.00% · $58.07
- T+5 · 3mo ago −0.05%α −1.26% · $58.86
- T+20 · 3mo ago +3.87%α +3.27% · $61.17
- T+60 · 18d ago +6.32%α +7.74% · $62.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two top executives at Vaxcyte, the CEO and CFO, sold a combined $395K in open-market stock over a one-week window, with the CFO's sale following a derivative exercise. The total dollar value is only ~0.005% of the $8.1B market cap, making this a routine, immaterial cluster. No insider buying occurred, and the sales are consistent with standard post-vesting diversification, not a bearish signal on the company's pipeline or prospects.
Key Financial Metrics
Key Facts
- CEO Grant Pickering sold 378 shares for ~$21K on 2026-07-27.
- CFO Andrew Guggenhime sold ~10,000 shares total for ~$374K on 2026-08-03, following derivative exercises.
- Total open-market sales of ~$395K represent ~0.005% of Vaxcyte's $8.1B market cap.
- No insider purchases were made during the cluster window.
- The cluster is small in both absolute and relative terms, consistent with routine portfolio management.
Financial Impact
Total insider sales of ~$395K, or ~0.005% of market cap, trivial and non-material.
Risk Factors
- No bearish signal from this cluster; the stock remains driven by clinical trial outcomes.
- If future insider selling accelerates beyond routine vesting-related transactions, it could signal reduced confidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PCVX-1786003639690 |
Track record
29 reports on PCVX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.40 Now $61.61 −1.27% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $64.69 Now $61.61 −4.76% settles Dec 11
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $61.61 −3.57% settles Dec 7
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $61.61 −3.57% settles Dec 7
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
- Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $61.61 +12.80% ▲ +4.42% +1.15% vs SPY
- Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $61.61 +13.69% ▲ +10.49% +4.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers